


Supplemental Figures

Figure e-1. Absolute Standardized Difference Plot: Pre and Post ATT Weighting



Standardized difference plot comparing baseline covariates between DMF and FTY before and after Average Treatment Effect on the Treated (ATT) weighting using the linear propensity score. Positive values represent higher standardized effect sizes for DMF. Variables include ps (continuous), linps (continuous), MRI Lesion Burden (mild, moderate, severe), Age (continuous), Drug Switch (none, interferon, glatiramer, natalizumab, immunosuppression, other), Race (white, black, other), MS type (relapsing-remitting, progressive), GdE lesions (present, not present), Sex (female, male) and disease duration (continuous). Abbreviations: linps, linear propensity score; ps, propensity score




Figure e-2. (a) Kaplan-Meier plot of disease modifying therapy (DMT) discontinuation through 24-month follow-up. (b) Kaplan-Meier plot of disease modifying therapy (DMT) discontinuation due to intolerability through 24-month follow-up. (c) Kaplan-Meier plot of disease modifying therapy (DMT) discontinuation due to MRI disease activity through 24-month follow-up. CI: confidence interval; DMF: dimethyl fumarate; FTY: fingolimod; HR: hazard ratio.